📰 Recommended Phase News
Page 2 - Recommended Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recommended Phase. Real-time updates on events, politics, business and more.
October 12, 2023
PMV Pharmaceuticals, Inc. announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE clinical trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple...
October 12, 2023
12.10.2023 - Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, breast, ... Seite 1
September 18, 2023
– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Companys Annamycin clinical trials – Next generation anthracycline,...
September 18, 2023
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
September 6, 2023
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript September 5, 2023 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $2.16, expectations were $-2.68. Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a […]
September 5, 2023
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
August 10, 2023
/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
August 10, 2023
– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML...
July 24, 2023
24 July 2023 ORYZON reports financial results and corporate updates for half-year ending June 30, 2023 Positive aggregate safety data from...
July 24, 2023
24.07.2023 - Positive aggregate safety data from vafidemstats PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-toleratedContinues to enroll ...